Written answers

Wednesday, 26 January 2022

Department of Health

Cross-Border Co-operation

Photo of Brendan SmithBrendan Smith (Cavan-Monaghan, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

198. To ask the Minister for Health when costings will be revised in respect of the costs of treatment outside Ireland’s jurisdiction under the Cross-Border Healthcare Directive to ensure adequate reimbursement for patients; and if he will make a statement on the matter. [3948/22]

Photo of Stephen DonnellyStephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

The EU Cross Border Directive (CBD) provides rules for the reimbursements to patients of the cost of receiving treatment abroad, where the patient would be entitled to such treatment in their home Member State, and supplements the rights that patients already have at EU level. The CBD enables persons resident in the State to access and be reimbursed for healthcare in another Member State by the HSE, provided such healthcare is publicly available within Ireland.

Reimbursement under this scheme is made at the lesser of either the cost of the treatment in Ireland, or the cost of the treatment incurred by the patient in the other State. Details are available from the HSE's CBD National Contact Point (NCP). It is important to note that reimbursement is confined to the costs of the care itself and does not include any additional costs, such as travel or accommodation costs, incurred by the patient. Reimbursement rates are set by the HSE. And are those applicable to the cost of treatment in the Public Health Service in Ireland.

Comments

No comments

Log in or join to post a public comment.